3.1 Comparison of general baseline data between MACE group and non-MACE group
Over a median 40.56±18.33month follow-up period, 30/357 patients (8.40%) were lost to follow-up. Those with incomplete data (n = 3) and patients < 18 years (n = 24) were excluded from this report. Finally, 300 HCM patients were included in our final analyses.Of these patients, 39.00% (117/300) suffered from a MACE, including 40 cases of all-cause death, 29 cases of cardiovascular mortality. Patients were thus separated into a MACE group and a non-MACE group (183 and 117 patients, respectively). Compared to those in the non-MACE group, patients in the MACE group were older, and had higher rates of coronary artery disease (CAD) and atrial fibrillation (AF). Individuals in the MACE group also exhibited lower Hb, HCT, and MCHC but higher serum Cr, NT-proBNP, LVMI and RDW levels compared to those in the non-MACE group (P <0.05). (Table 1)